Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,255
datasets available to search
ShareScore release 0.9.0
Dataset results
3,255 results for “Pancreatic Cancer”
Hedgehog signaling alters the balance of fibroblast subtypes in pancreatic cancer [bulk RNA-seq]
GEO Series GSE156866. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
MAP Kinase inhibition depletes tumor-infiltrating macrophages in mouse pancreatic cancer [Verona]
GEO Series GSE138477. Mus musculus. 13 samples. Type: Other.
Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy [ATAC-seq]
GEO Series GSE254919. Mus musculus. 12 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer [ATAC-seq].
GEO Series GSE166510. Mus musculus. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Pancreatic cancer drug treatment study
GEO Series GSE2646. Homo sapiens. 2 samples. Type: Expression profiling by array.
Local ablation disrupts immune evasion in pancreatic cancer [RNA-seq 2]
GEO Series GSE214205. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
CFL1-induced super enhancer RNA m6A modification promotes local chromatin accessibility and oncogenes transcription in pancreatic cancer
GEO Series GSE211589. Homo sapiens. 87 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Methylation profiling by high throughput sequencing.
A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Zheng et al.
GEO Series GSE273398. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Blood biomarkers of pancreatic cancer associated diabetes identified by peripheral blood-based gene expression profiles
GEO Series GSE15932. Homo sapiens. 32 samples. Type: Expression profiling by array.
Dataset related to article "Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? "
<p>This record contains raw data related to article "Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?"</p><p><strong>Abstract</strong></p><p>Neoadjuvant therapy (NAT) + surgical resection for pancreatic cancer (PC) has gained consensus in recent years. Pathological response (PR) is generally assessed according to the College of American Pathologists grading system, ranging from 0 (complete response) to 3 (no response). The aim of our study is to evaluate the PR in a series of resections for PC after NAT and its prognostic implication. 112 patients undergone NAT and resection for PC between 2011 and 2020 were retrospectively evaluated. PR was 0/1, 2 and 3 in 18 (15%), 79 (61%) and 29 (24%) cases, respectively. Chemotherapy regimens different from FOLFIRINOX and gemcitabine + nab-paclitaxel (OR 11.61 (2.53-53.36), p = 0.002) and lymphovascular invasion (OR 11.28 (1.89-67.23), p = 0.008) were associated to PR-3. Median follow-up was 25.8 (3.6-130.5) months. For PR-0/1, PR-2 and PR-3, median DFS was 45.8, 11.5, 4.6 months (p < 0.0001), respectively, while median OS was not reached, 27.1 and 17.5 months (p = 0.0006), respectively. At univariate analysis, PR-0/1 was significantly associated to better DFS and OS (HR 0.33 (0.17-0.67), p = 0.002; HR 0.20 (0.07-0.54), p = 0.002, respectively). At multivariate analysis, pancreaticoduodenectomy (HR 0.50 (0.30-0.84), p = 0.009), LNR (HR 27.14 (1.21-608.9), p = 0.038) and lymphovascular invasion (HR 1.99 (1.06-3.76), p = 0.033) were independently associated to DFS; pre-treatment CA 19.9 value (HR 1.00 (1.00-1.00), p = 0.025), post-treatment resectability status (HR 0.51 (0.28-0.95), p = 0.035), pancreaticoduodenectomy (HR 0.56 (0.32-0.99), p = 0.050), severe morbidity (2.99 (1.22-7.55), p = 0.017), LNR (HR 56.8 (2.08-1548.3), p = 0.017), lymphovascular invasion (HR 2.18 (1.08-4.37), p = 0.029) were independently associated to OS. PR did not reach statistical significance at multivariate analysis. A favorable PR is observed only in a limited number of cases. The prognostic role of PR, despite being promising, remains unclear and further multicentric studies are needed.</p>
Dataset related to article "Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis"
<p>This record contains raw data related to article "Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis"</p><p> Abstract</p><p>We investigate the prevalence of germline mutations in cancer predisposition genes in patients with pancreatic ductal adenocarcinoma (PDAC) or suspected related hereditary syndromes.</p><p>Methods: we enrolled for NGS with an Illumina TrueSight Cancer panel comprising 19 CPGs and 113 consecutive subjects referred to cancer genetic clinics for metastatic PDAC, early onset PDAC, suspected hereditary syndrome, or positive family history.</p><p>Results: Overall, 23 (20.1%) subjects were carriers of 24 pathogenetic variants (PVs). We found 9 variants in BRCA2 (37.5%), 6 in CDKN2A (25%), 3 in ATM (12.5%), 2 in BRCA1 (8.3%), 1 in CHEK2 (4.1%), 1 in PALB2 (4.1%), 1 in MITF (4.1%), and 1 in FANCM (4.1%). A double PV (BRCA1 plus BRCA2) was found in 1 subject. We observed a nearly 30% (16/55) mutational rate in the subgroup of subjects tested for the suspected syndromes (PDAC and other synchronous or metachronous tumors or an indicative family history), and the frequency was significantly higher than that in patients with only metastatic PDAC (p = 0.05). In our cohort, 39 variants of unknown significance (VUS) were identified, most of which (16/39, 41%) in genes belonging to the Lynch syndrome spectrum.</p><p>Conclusion: A clinically relevant proportion of pancreatic cancer is associated with mutations in known predisposition genes. Guidelines instructing on an adequate selection for accessing genetic testing are eagerly needed. The heterogeneity of mutations identified in this study reinforces the value of using a multiple-gene panel in pancreatic cancer.</p><p> </p>
In vivo CRISPR screening identifies ISL2 as a tumor suppressor and regulator of metabolic gene expression in pancreatic cancer (RNA-Seq)
GEO Series GSE180901. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival [ChIPseq]
GEO Series GSE309860. Homo sapiens. 12 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Sin3B loss enhances the T-cell inflamed tumor microenvironment through the redistribution of H3K27Ac signals in pancreatic cancer [CUT&Tag]
GEO Series GSE254767. Mus musculus. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer progression via extracellular vesicle transfer of m6A-modified RNAs
GEO Series GSE241850. Mus musculus. 57 samples. Type: Expression profiling by high throughput sequencing; Other.
Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer
GEO Series GSE34189. Mus musculus. 6 samples. Type: Expression profiling by array.
Effect of depletion of TRIP12 on gene expression in adult murine pancreatic acinar cells and murine pancreatic cancer cell lines
GEO Series GSE221587. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Annexin-A1-mediated regulation of the efferocytosis in tumor-associated macrophage promotes anti-tumor immune response by activating the cGAS/STING pathway in pancreatic cancer
GEO Series GSE255146. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells
GEO Series GSE19281. Homo sapiens. 37 samples. Type: Expression profiling by array.
Expression analysis of human pancreatic cancer cell lines (Capan-1, Panc-1, Panc-1+ve and Panc-1-ve) and pancreatic ductal cell line (HPDE)
GEO Series GSE42428. Homo sapiens. 5 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.